Edward G. Garmey

1.8k total citations
36 papers, 1.3k citations indexed

About

Edward G. Garmey is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Edward G. Garmey has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Edward G. Garmey's work include Lung Cancer Treatments and Mutations (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Edward G. Garmey is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer, Hypoxia, and Metabolism (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Edward G. Garmey collaborates with scholars based in United States, Canada and Taiwan. Edward G. Garmey's co-authors include Brian Schwartz, Joachim von Pawel, Joan H. Schiller, Dora Ferrari, Lecia V. Sequist, Rodryg Ramlau, Wallace Akerley, David E. Gerber, С. В. Орлов and Wolfram Brugger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Edward G. Garmey

35 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward G. Garmey United States	15	514	499	452	303	190	36	1.3k
Jun‐Eul Hwang South Korea	25	477 0.9×	663 1.3×	458 1.0×	144 0.5×	262 1.4×	108	1.8k
Kathryn Field Australia	21	324 0.6×	539 1.1×	173 0.4×	115 0.4×	211 1.1×	75	1.3k
Andrea Mambrini Italy	22	453 0.9×	829 1.7×	212 0.5×	436 1.4×	191 1.0×	109	1.5k
Yizhou Jiang United States	22	392 0.8×	1.0k 2.0×	465 1.0×	233 0.8×	149 0.8×	93	1.9k
Mihaela Cristea United States	25	307 0.6×	1.3k 2.5×	506 1.1×	35 0.1×	183 1.0×	110	2.2k
Muhammad S. Beg United States	13	143 0.3×	264 0.5×	654 1.4×	108 0.4×	535 2.8×	24	1.2k
Joshua E. Meyer United States	21	640 1.2×	1.1k 2.3×	279 0.6×	78 0.3×	286 1.5×	113	2.2k
Lisa M. Landrum United States	24	396 0.8×	829 1.7×	520 1.2×	48 0.2×	348 1.8×	87	2.9k
Jaekyung Cheon South Korea	22	365 0.7×	720 1.4×	166 0.4×	477 1.6×	179 0.9×	92	1.4k
Noriyo Yamashiki Japan	25	303 0.6×	273 0.5×	194 0.4×	1.6k 5.3×	161 0.8×	89	2.3k

Countries citing papers authored by Edward G. Garmey

Since Specialization

Citations

This map shows the geographic impact of Edward G. Garmey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward G. Garmey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward G. Garmey more than expected).

Fields of papers citing papers by Edward G. Garmey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward G. Garmey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward G. Garmey. The network helps show where Edward G. Garmey may publish in the future.

Co-authorship network of co-authors of Edward G. Garmey

This figure shows the co-authorship network connecting the top 25 collaborators of Edward G. Garmey. A scholar is included among the top collaborators of Edward G. Garmey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward G. Garmey. Edward G. Garmey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsai, Frank, Michael J. Birrer, Jason R. Brown, et al.. (2024). A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.. Journal of Clinical Oncology. 42(16_suppl). 3112–3112. 2 indexed citations

Malhotra, Jyoti, Mona Arbab, Matthew P. Deek, et al.. (2024). Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.. Journal of Clinical Oncology. 42(16_suppl). TPS2685–TPS2685. 4 indexed citations

Minchom, Anna, Edward G. Garmey, Lukas Makris, et al.. (2024). 680TiP A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies. Annals of Oncology. 35. S530–S530. 1 indexed citations

Moser, Justin C., Angela Alistar, Ezra E.W. Cohen, et al.. (2023). 618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors. SHILAP Revista de lepidopterología. A704–A704. 4 indexed citations

Chung, Vincent, Komal Jhaveri, Daniel D. Von Hoff, et al.. (2021). Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 2548–2548. 16 indexed citations

Chao, Joseph, James Lin, Paul Frankel, et al.. (2017). Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. Journal of Gastrointestinal Oncology. 8(6). 962–969. 24 indexed citations

Tian, Xi, Minh Nguyen, Henry P. Foote, et al.. (2016). CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α. Cancer Research. 77(1). 112–122. 72 indexed citations

Chao, Joseph, Yi-Chan Lin, Paul Frankel, et al.. (2016). Pilot trial of CRLX101 in patients (pts) with advanced, chemotherapy-refractory gastroesophageal cancer (GEC).. Journal of Clinical Oncology. 34(4_suppl). 44–44. 1 indexed citations

O’Keefe, Stephen J., Jean Hoffman‐Censits, Roger B. Cohen, et al.. (2016). Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial. Annals of Oncology. 27(8). 1579–1585. 47 indexed citations

10.

Wang, Andrew Z., Xi Tian, Minh Nguyen, et al.. (2015). Improving neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, a nanoparticle-drug conjugate, with a camptothecin payload.. Journal of Clinical Oncology. 33(3_suppl). 645–645. 1 indexed citations

11.

O’Keefe, Stephen J., Jean Hoffman‐Censits, Ronac Mamtani, et al.. (2015). HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).. Journal of Clinical Oncology. 33(15_suppl). 4543–4543. 1 indexed citations

12.

Pham, Elizabeth, Michael J. Birrer, Scott Eliasof, et al.. (2014). Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer. Clinical Cancer Research. 21(4). 808–818. 77 indexed citations

13.

O’Keefe, Stephen J., Meliessa Hennessy, Ronac Mamtani, et al.. (2014). Abstract CT340: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): results from the planned interim analysis. Cancer Research. 74(19_Supplement). CT340–CT340. 3 indexed citations

14.

O’Keefe, Stephen J., Daniel F. Heitjan, Amy Marshall, et al.. (2014). Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 32(4_suppl). 412–412. 4 indexed citations

15.

Krasner, Carolyn, Michael J. Birrer, Suzanne Berlin, et al.. (2014). Phase II clinical trial evaluating CRLX101 in recurrent ovarian, tubal, and peritoneal cancer.. Journal of Clinical Oncology. 32(15_suppl). 5581–5581. 8 indexed citations

16.

Goldman, Jonathan W., Isett Laux, Fang Chai, et al.. (2012). Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 118(23). 5903–5911. 71 indexed citations

17.

Sequist, Lecia V., Joachim von Pawel, Edward G. Garmey, et al.. (2011). Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(24). 3307–3315. 322 indexed citations

18.

Kayton, Mark L., Edward G. Garmey, Nicole Ishill, et al.. (2010). Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections. Journal of Pediatric Surgery. 45(10). 1961–1966. 36 indexed citations

19.

Garmey, Edward G., Oliver Sartor, Susan Halabi, & Nicholas J. Vogelzang. (2008). Second-line chemotherapy for advanced hormone-refractory prostate cancer.. PubMed. 6(2). 118–22, 127. 26 indexed citations

20.

Thior, Ibou, Janet A. Grimes, Roger Shapiro, et al.. (2006). Voluntary counseling and testing among post-partum women in Botswana. Patient Education and Counseling. 65(3). 296–302. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact